M
Marie Helleberg
Researcher at University of Copenhagen
Publications - 129
Citations - 2888
Marie Helleberg is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 22, co-authored 99 publications receiving 1927 citations. Previous affiliations of Marie Helleberg include Copenhagen University Hospital & National Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Mortality Attributable to Smoking Among HIV-1–Infected Individuals: A Nationwide, Population-Based Cohort Study
Marie Helleberg,Shoaib Afzal,Gitte Kronborg,Carsten Schade Larsen,Gitte Pedersen,Court Pedersen,Jan Gerstoft,Børge G. Nordestgaard,Børge G. Nordestgaard,Niels Obel +9 more
TL;DR: In a setting where HIV care is well organized and antiretroviral therapy is free of charge, HIV-infected smokers lose more life-years to smoking than to HIV.
Journal ArticleDOI
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.
Marie Helleberg,Margaret T May,Suzanne M Ingle,François Dabis,Peter Reiss,Peter Reiss,Gerd Fätkenheuer,Gerd Fätkenheuer,Dominique Costagliola,Antonella d’Arminio,Matthias Cavassini,Colette Smith,Amy C. Justice,John Gill,Jonathan A C Sterne,Niels Obel +15 more
TL;DR: Excess mortality associated with smoking increases markedly with age, and increases in smoking-related mortality can be expected as the treated HIV-infected population ages.
Journal ArticleDOI
Myocardial Infarction Among Danish HIV-Infected Individuals: Population-Attributable Fractions Associated With Smoking
Line D Rasmussen,Marie Helleberg,Margaret T May,Shoaib Afzal,Gitte Kronborg,Carsten Schade Larsen,Court Pedersen,Jan Gerstoft,Børge G. Nordestgaard,Niels Obel +9 more
TL;DR: Smoking is associated with a higher risk of MI in the HIV-infected population than in the general population, and smoking cessation should be a primary focus in modern HIV care.
Journal ArticleDOI
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.
Marie Warrer Munch,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Sanjith Saseedharan,Thomas Benfield,Rebecka Rubenson Wahlin,Bodil Steen Rasmussen,Anne Sofie Andreasen,Lone Musaeus Poulsen,Luca Cioccari,Mohd Saif Khan,Farhad N Kapadia,Jigeeshu V Divatia,Anne Craveiro Brøchner,Morten H. Bestle,Marie Helleberg,Jens Michelsen,Ajay Padmanaban,Neeta Bose,Anders Pape Møller,Kapil Borawake,Klaus Tjelle Kristiansen,Urvi Shukla,Michelle S Chew,Subhal Dixit,Charlotte Suppli Ulrik,Pravin Amin,Rajesh Chawla,Christian A Wamberg,Mehul S Shah,Iben S Darfelt,Vibeke Lind Jørgensen,Margit Smitt,Anders Granholm,Maj-Brit Nørregaard Kjaer,Morten Hylander Møller,Tine Sylvest Meyhoff,Gitte Kingo Vesterlund,Naomi E Hammond,Naomi E Hammond,Sharon Micallef,Abhinav Bassi,Oommen John,Oommen John,Anubhuti Jha,Maria Cronhjort,Stephan M. Jakob,Christian Gluud,Christian Gluud,Theis Lange,Vaijayanti Kadam,Klaus Marcussen,Jacob Hollenberg +52 more
TL;DR: In this article, the effects of 12 mg vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia were evaluated in a randomized clinical trial at 26 hospitals in Europe and India.
Journal ArticleDOI
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
Marie Helleberg,Carsten Utoft Niemann,Kasper Sommerlund Moestrup,Ole Kirk,Anne-Mette Lebech,Clifford Lane,Jens D Lundgren +6 more
TL;DR: It is demonstrated suppressive but not curative effect of remdesivir in an immunocompromised patient treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia.